Monitor outcomes to ensure long-term PRRS control success. Track diagnostic results and pig performance data across sow, grow-finish, and whole production systems to detect low-level virus circulation, guide decisions, and move herds toward stable or negative status.
The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
Porcine reproductive and respiratory syndrome (PRRS) is an infectious disease caused by the PRRS virus (PRRSV) and characterized by reproductive failure, respiratory disease and weight loss in swine.
Cell-mediated immunity (CMI), IL-10, and the protective efficacy of modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines (MLV) against co-challenge with PRRSV-1 and PRRSV-2 (HP-PRRSV) were investigated.
This study evaluated porcine reproductive and respiratory syndrome virus (PRRSV)-2 modiied live virus (MLV) vaccine against heterologous single and dual challenge of Korean PRRSV-1 and PRRSV-2.
Type 2 porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) was first isolated in Korea in 1994. The commercial PRRS modified live vaccine (Ingelvac1 PRRS MLV, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, USA) based on type 2 PRRSV, was first licensed for use in 3- to 18-week-old pigs in Korea in 1996.